Skip to main content
S

Sirio Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 300791 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,171 across all filing types
Latest filing 2026-04-23 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300791

About Sirio Pharma Co., Ltd.

https://www.siriopharma.com

Sirio Pharma Co., Ltd. is a global contract development and manufacturing organization (CDMO) specializing in dietary supplements and nutraceuticals. The company provides comprehensive services encompassing product formulation, manufacturing, and packaging. Its portfolio includes diverse delivery formats such as softgels, gummies, tablets, hard capsules, powders, and oral liquids. Sirio Pharma emphasizes innovation in delivery systems, offering specialized solutions like plant-based softgels and advanced probiotic formulations. The organization adheres to rigorous quality management systems and maintains multiple international certifications to meet global regulatory standards. Serving an international clientele, the company supports health and wellness brands through scalable production capacities and integrated supply chain solutions.

Recent filings

Filing Released Lang Actions
广东信达律师事务所关于仙乐健康科技股份有限公司回购注销2023年、2025年限制性股票激励计划部分已授予但尚未解除限售的限制性股票相关事项的法律意见书
Transaction in Own Shares Classification · 1% confidence This document is a “法律意见书” (Legal Opinion) issued by a law firm concerning the repurchase and cancellation of restricted shares granted under the company’s 2023 and 2025 stock incentive plans. It is not an earnings release, annual report, board change notice, or proxy material, but rather a legal opinion supporting the company’s share repurchase and cancellation. Under the filing definitions, announcements and documentation relating to a company buying back or cancelling its own shares fall under Transaction in Own Shares (POS).
2026-04-23 Chinese
关于回购注销2023年限制性股票激励计划部分已授予但尚未解除限售的限制性股票的公告
Transaction in Own Shares Classification · 1% confidence The document is an official announcement by the company regarding the repurchase and cancellation of part of its own restricted shares under the 2023 restricted stock incentive plan. It details the board approvals, legal opinions, quantities, prices, and source of funds for the share buyback. This falls squarely under the “Transaction in Own Shares” category, which covers share repurchase activities. Therefore, the filing is classified as POS.
2026-04-23 Chinese
2026-072 关于关停个人护理业务的公告
Regulatory Filings Classification · 1% confidence The document is a corporate announcement about the company’s decision to shut down its personal care business following a board meeting resolution. It is not an earnings release, management change, M&A deal, or financial report, but rather a standard regulatory disclosure of an operational decision. It falls into the miscellaneous category of regulatory filings rather than a specific report type.
2026-04-23 Chinese
招商证券股份有限公司关于仙乐健康科技股份有限公司2025年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 1% confidence The document is a detailed “专项核查意见” (special verification opinion) on the storage, management, and use of funds raised by 仙乐健康科技股份有限公司 for 2025, including tables of fund balances, usage, and auditor (德勤华永会计师事务所) review opinions as well as sponsor (招商证券) opinions. It is not an Annual Report or earnings release but a standalone audit/verification report on the raised funds as required by regulators. This matches the “Audit Report / Information (AR)” category.
2026-04-23 Chinese
关于会计师事务所履职情况的评估报告
Audit Report / Information Classification · 1% confidence The document is titled “关于会计师事务履职情况的评估报告” and provides a detailed evaluation of the external auditor (Deloitte Huayong) performance, independence, and audit process for the 2025 fiscal year, including regulatory references, auditor credentials, scope of audit, and the board’s assessment. It is not the full annual report nor a brief announcement but a standalone audit‐related report required by corporate and securities laws. Therefore it falls under Audit Report / Information (AR).
2026-04-23 Chinese
关于增加公司对子公司申请银行授信预计提供担保进展的公告
Capital/Financing Update Classification · 1% confidence The document is a regulatory announcement by a listed company detailing the progress of providing joint‐and‐several guarantees for its subsidiary’s bank credit facilities (increasing guarantee amounts and summarizing terms). It is not a financial report, board change, dividend notice, or share issue, but rather an update on financing activities (the company’s provision of guarantees for debt). This aligns with the “Capital/Financing Update” category (CAP).
2026-04-15 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.